Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAmin AzemZKZena KomrokjiZXZhuoer Xie

Discussion

Loading...

Member takes

Overview

Analysis reveals IDH mutant myelodysplastic syndromes have unique clinical phenotype, implying improved survival with azacitidine therapy.

Key Points

  • IDH mutant myelodysplastic syndromes exhibit distinct clinical phenotype compared to wildtype.
  • Overall survival improves with azacitidine treatment in IDH mutant cases, suggesting treatment benefits.
  • Autoimmune-related diseases are more prevalent in patients with IDH mutations than in wildtype.
  • RUNX1 and TP53 mutations are common in IDH mutant myelodysplastic syndromes, indicating complex genetic interactions.

Cite This Study

Azem et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d84bhttps://doi.org/10.1182/blood-2025-3851
View Full Paper
Ask AI
Bookmark
Share